IL240443A0 - Antibodies against tnf-a with a high level of galactosylation and their uses - Google Patents

Antibodies against tnf-a with a high level of galactosylation and their uses

Info

Publication number
IL240443A0
IL240443A0 IL240443A IL24044315A IL240443A0 IL 240443 A0 IL240443 A0 IL 240443A0 IL 240443 A IL240443 A IL 240443A IL 24044315 A IL24044315 A IL 24044315A IL 240443 A0 IL240443 A0 IL 240443A0
Authority
IL
Israel
Prior art keywords
tnf
alpha antibodies
highly galactosylated
galactosylated anti
highly
Prior art date
Application number
IL240443A
Other languages
English (en)
Hebrew (he)
Original Assignee
Lab Francais Du Fractionnement
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lab Francais Du Fractionnement filed Critical Lab Francais Du Fractionnement
Publication of IL240443A0 publication Critical patent/IL240443A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39508—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from milk, i.e. lactoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/04—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/12—Immunoglobulins specific features characterized by their source of isolation or production isolated from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL240443A 2013-02-13 2015-08-09 Antibodies against tnf-a with a high level of galactosylation and their uses IL240443A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361764475P 2013-02-13 2013-02-13
PCT/IB2014/000692 WO2014125374A2 (en) 2013-02-13 2014-02-13 Highly galactosylated anti-tnf-alpha antibodies and uses thereof

Publications (1)

Publication Number Publication Date
IL240443A0 true IL240443A0 (en) 2015-09-24

Family

ID=50980321

Family Applications (1)

Application Number Title Priority Date Filing Date
IL240443A IL240443A0 (en) 2013-02-13 2015-08-09 Antibodies against tnf-a with a high level of galactosylation and their uses

Country Status (14)

Country Link
US (3) US10174110B2 (https=)
EP (3) EP3594231A1 (https=)
JP (2) JP2016508515A (https=)
KR (1) KR20160002713A (https=)
CN (1) CN105308068A (https=)
AR (1) AR094780A1 (https=)
AU (1) AU2014217561B2 (https=)
BR (1) BR112015019341A2 (https=)
CA (1) CA2900909A1 (https=)
ES (1) ES2755181T3 (https=)
IL (1) IL240443A0 (https=)
MX (1) MX2015010427A (https=)
TW (1) TW201506041A (https=)
WO (1) WO2014125374A2 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8164343B2 (en) 2003-09-05 2012-04-24 Midtronics, Inc. Method and apparatus for measuring a parameter of a vehicle electrical system
KR20140093603A (ko) 2010-12-30 2014-07-28 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 병원체 불활성화제로서의 글리콜
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
EP3594231A1 (en) 2013-02-13 2020-01-15 Laboratoire Français du Fractionnement et des Biotechnologies Highly galactosylated anti-tnf-alpha antibodies and uses thereof
US10034921B2 (en) 2013-02-13 2018-07-31 Laboratoire Français Du Fractionnement Et Des Biotechnologies Proteins with modified glycosylation and methods of production thereof
EP2956485A2 (en) * 2013-02-13 2015-12-23 Laboratoire Français du Fractionnement et des Biotechnologies Highly galactosylated anti-her2 antibodies and uses thereof
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
MX384222B (es) 2013-07-05 2025-03-14 Lab Francais Du Fractionnement Matriz de cromatografia de afinidad.
KR102313341B1 (ko) * 2013-08-26 2021-10-18 바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 시알릴-루이스 ａ에 대한 사람 항체 코드화 핵산
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
FR3022462B1 (fr) * 2014-06-18 2018-04-27 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Composition orale d'anticorps anti-tnfalpha
SG11201700446XA (en) 2014-07-21 2017-02-27 Glykos Finland Oy Production of glycoproteins with mammalian-like n-glycans in filamentous fungi
FR3034419B1 (fr) 2015-04-02 2017-12-15 Lab Francais Du Fractionnement Procede de purification d'une proteine recombinante therapeutique a partir d'un lait transgenique
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
EP3257866A1 (en) * 2016-06-17 2017-12-20 Academisch Medisch Centrum Modified anti-tnf antibody and use thereof in the treatment of ibd
FR3054444A1 (fr) 2016-07-29 2018-02-02 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Composition orale d'anticorps anti-tnf alpha
EP3581203A1 (en) * 2018-06-11 2019-12-18 Laboratoire Français du Fractionnement et des Biotechnologies Antibodies with increased activity in the digestive tract
CN116903738A (zh) * 2022-08-02 2023-10-20 北京绿竹生物技术股份有限公司 一种低甘露糖型抗人肿瘤坏死因子-α单抗及其用途
EP4630056A2 (en) * 2022-12-09 2025-10-15 Xentria, Inc. Methods of treating sarcoidosis with a tnf-a antibody and associated compositions and methods
TW202525846A (zh) 2023-08-25 2025-07-01 美商普羅特歐拉吉克適美國公司 抗ｉｌ—１３多特異性抗體構築體及其用途
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease

Family Cites Families (183)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE122007000007I1 (de) 1986-04-09 2007-05-16 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US6727405B1 (en) 1986-04-09 2004-04-27 Genzyme Corporation Transgenic animals secreting desired proteins into milk
GB8615942D0 (en) 1986-06-30 1986-08-06 Animal & Food Research Council Peptide production
US5366894A (en) 1986-06-30 1994-11-22 Pharmaceutical Proteins Limited Peptide production
AU7879987A (en) 1986-08-28 1988-03-24 Immunex Corp. Expression of heterologous proteins by transgenic lactating mammals
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
GB8826446D0 (en) 1988-11-11 1988-12-14 Agricultural & Food Res Peptide production
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
CA2075206C (en) 1989-12-01 2006-05-23 Herbert L. Heyneker Production of recombinant polypeptides by bovine species and transgenic methods
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE4000939A1 (de) 1990-01-15 1991-07-18 Brem Gottfried Prof Dr Dr Verfahren zur antikoerpergewinnung
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE4028800A1 (de) 1990-09-11 1992-03-12 Behringwerke Ag Gentechnische sialylierung von glykoproteinen
US5648253A (en) 1990-12-20 1997-07-15 Tsi Corporation Inhibitor-resistant urokinase
US5965789A (en) 1991-01-11 1999-10-12 American Red Cross Engineering protein posttranslational modification by PACE/furin in transgenic non-human mammals
AU1228592A (en) 1991-01-11 1992-08-17 American Red Cross Expression of active human protein c in mammary tissue of transgenic animals
US5831141A (en) 1991-01-11 1998-11-03 United States Of America As Represented By The Department Of Health And Human Services Expression of a heterologous polypeptide in mammary tissue of transgenic non-human mammals using a long whey acidic protein promoter
JPH06509474A (ja) 1991-07-31 1994-10-27 ローヌ−プーラン・ローラー・インターナシヨナル（ホールデイングス）インコーポレイテツド 蛋白質のトランスジェニック生産
US6448469B1 (en) 1991-10-02 2002-09-10 Genzyme Corporation Production of membrane proteins in the milk of transgenic nonhuman mammals
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
DE69424687T2 (de) 1993-03-09 2000-09-07 Genzyme Corp., Cambridge Verfahren zur isolierung von proteinen aus milch
DE4326665C2 (de) 1993-08-09 1995-07-13 Biotest Pharma Gmbh Verfahren zur Sterilfiltration von Milch
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5639940A (en) 1994-03-03 1997-06-17 Pharmaceutical Proteins Ltd. Production of fibrinogen in transgenic animals
US6204431B1 (en) 1994-03-09 2001-03-20 Abbott Laboratories Transgenic non-human mammals expressing heterologous glycosyltransferase DNA sequences produce oligosaccharides and glycoproteins in their milk
MX198456B (es) 1994-03-09 2000-09-05 Abbott Lab Animales trangenicos que producen oligosacaridos y glucoconjugados.
US5750176A (en) 1994-03-09 1998-05-12 Abbott Laboratories Transgenic non-human mammal milk comprising 2'-fucosyl-lactose
WO1995024494A1 (en) 1994-03-09 1995-09-14 Abbott Laboratories Humanized milk
EP0690452A3 (en) 1994-06-28 1999-01-07 Advanced Micro Devices, Inc. Electrically erasable memory and method of erasure
US5780009A (en) 1995-01-20 1998-07-14 Nexia Biotechnologies, Inc. Direct gene transfer into the ruminant mammary gland
US5843705A (en) 1995-02-21 1998-12-01 Genzyme Transgenic Corporation Transgenically produced antithrombin III
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
GB9517780D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
DK0929578T3 (da) 1996-02-09 2003-08-25 Abbott Lab Bermuda Ltd Humane antistoffer, der binder human TNFalfa
US6268487B1 (en) 1996-05-13 2001-07-31 Genzyme Transgenics Corporation Purification of biologically active peptides from milk
EP0849275A1 (en) 1996-09-26 1998-06-24 Rijksuniversiteit te Leiden Mannosylated peptides
EP0941310A1 (en) 1996-10-11 1999-09-15 THE TEXAS A&M UNIVERSITY SYSTEM Methods for the generation of primordial germ cells and transgenic animal species
US6063905A (en) 1997-01-07 2000-05-16 Board Of Regents, The University Of Texas System Recombinant human IGA-J. chain dimer
US5945577A (en) 1997-01-10 1999-08-31 University Of Massachusetts As Represented By Its Amherst Campus Cloning using donor nuclei from proliferating somatic cells
WO1998037224A1 (en) 1997-02-25 1998-08-27 Genzyme Transgenics Corporation Transgenically produced non-secreted proteins
WO1998045419A1 (en) 1997-04-03 1998-10-15 Universite Laval Transgenic expression in genital tract and sexual accessory glands
BR9809186A (pt) 1997-05-29 2000-08-01 Pastoral Agric Res Inst Nz Ltd Processos para a produção de imunoglobulina a um leite
US6210736B1 (en) 1997-06-17 2001-04-03 Genzyme Transgenics Corporation Transgenically produced prolactin
WO1999020766A2 (en) 1997-10-20 1999-04-29 Genzyme Transgenics Corporation NOVEL MODIFIED NUCLEIC ACID SEQUENCES AND METHODS FOR INCREASING mRNA LEVELS AND PROTEIN EXPRESSION IN CELL SYSTEMS
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
US20050181482A1 (en) 2004-02-12 2005-08-18 Meade Harry M. Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk
ATE339507T1 (de) 1998-06-15 2006-10-15 Gtc Biotherapeutics Inc Erythropoietin-analog-menschliches serum-albumin fusionsprotein
US20030005468A1 (en) 1998-06-19 2003-01-02 Meade Harry M. Methods and vectors for improving nucleic acid expression
US20040117863A1 (en) 1998-09-18 2004-06-17 Edge Michael D. Transgenically produced fusion proteins
EP1818397A1 (en) 1998-11-02 2007-08-15 Trustees Of Tufts College Methods for cloning animals
US6580017B1 (en) 1998-11-02 2003-06-17 Genzyme Transgenics Corporation Methods of reconstructed goat embryo transfer
US20030177513A1 (en) 1998-11-02 2003-09-18 Yann Echelard Transgenic and cloned mammals
CA2351943A1 (en) 1998-11-19 2000-06-02 Pharming Intellectual Property B.V. Stabilisation of milk from transgenic animals
US7208576B2 (en) 1999-01-06 2007-04-24 Merrimack Pharmaceuticals, Inc. Non-glycosylated human alpha-fetoprotein, methods of production, and uses thereof
JP2002537346A (ja) 1999-02-22 2002-11-05 エリック・エフ・バーンスタイン 光老化の保護用組成物および保護方法
WO2001000855A1 (en) 1999-06-23 2001-01-04 Ppl Therapeutics (Scotland) Ltd. Fusion proteins incorporating lysozyme
NZ518263A (en) 1999-10-14 2004-03-26 Gtc Biotherapeutics Inc Methods of producing a target molecule in a transgenic animal and purification of the target molecule
US7414170B2 (en) 1999-11-19 2008-08-19 Kirin Beer Kabushiki Kaisha Transgenic bovines capable of human antibody production
US7067713B2 (en) 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
NZ520472A (en) 2000-02-03 2004-03-26 Lennart Hammarstrom Ruminant MHC class I-like Fc receptors
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
HUP0302396A2 (hu) 2000-05-05 2003-10-28 Gtc Biotherapeutics, Inc. Transzgénikus úton előállított dekorin
JP2004500890A (ja) 2000-06-19 2004-01-15 ジーティーシー　バイオセラピューティックス　インコーポレイテッド 遺伝子導入によって作成された血小板由来増殖因子
EP2322644A1 (en) 2000-06-28 2011-05-18 GlycoFi, Inc. Methods for producing modified glycoproteins
US6924412B1 (en) 2000-07-21 2005-08-02 Arriwan Holding B.V. Means and methods for raising antibody concentration in compartments of the body of a non-human animal
JP2004505624A (ja) 2000-08-10 2004-02-26 ジーティーシー　バイオセラピューティックス　インコーポレイテッド 精子の低温保存
CA2424977C (en) 2000-10-06 2008-03-18 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US20040226052A1 (en) 2000-10-13 2004-11-11 Meade Harry M. Methods of producing a target molecule in a transgenic animal and purification of the target molecule
NZ526720A (en) 2000-12-28 2007-11-30 Altus Pharmaceuticals Inc Crystallisation of whole antibodies or fragments thereof, on a large scale and a process allowing an alternative route for delivery of therapeutic antibodies
US20030036637A1 (en) 2001-06-13 2003-02-20 Scott Fulton Purification of human serum albumin
DK1399484T3 (da) 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
EP2180044A1 (en) 2001-08-03 2010-04-28 GlycArt Biotechnology AG Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity
AU2002364935A1 (en) 2001-10-09 2003-06-23 Mayo Foundation For Medical Education And Research Enhancement of immune responses by 4-1bb-binding agents
EP2042196B1 (en) 2001-10-10 2016-07-13 ratiopharm GmbH Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF)
US7053202B2 (en) 2001-10-19 2006-05-30 Millennium Pharmaceuticals, Inc. Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
US20060253913A1 (en) 2001-12-21 2006-11-09 Yue-Jin Huang Production of hSA-linked butyrylcholinesterases in transgenic mammals
US20040133931A1 (en) 2003-01-08 2004-07-08 Gavin William G. Method and system for fusion and activation following nuclear transfer in reconstructed embryos
CA2470195A1 (en) 2002-01-11 2003-08-07 Gtc Biotherapeutics, Inc. Method and system for fusion and activation following nuclear transfer in reconstructed embryos
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
KR20100117148A (ko) 2002-04-01 2010-11-02 지티씨바이오쎄라퓨틱스,인크. 폐 질환의 치료 방법
US20030204860A1 (en) 2002-04-01 2003-10-30 David Melican Method for selecting cell lines to be used for nuclear transfer in mammalian species
EP1543034A4 (en) 2002-07-15 2006-11-08 Mayo Foundation TREATMENT AND PROPHYLAXIS WITH 4-1BB BINDING AGENTS
CA2501415A1 (en) 2002-08-01 2004-02-12 Gtc Biotherapeutics, Inc. Method of selecting cells for somatic cell nuclear transfer
WO2004026427A2 (en) 2002-09-17 2004-04-01 Gtc Biotherapeutics, Inc. Isolation of immunoglobulin molecules that lack inter-heavy chain disulfide bonds
AU2003295584A1 (en) 2002-11-18 2004-06-15 Taurus Hsa Llc Method for continuous, automated blending of solutions from acids and bases
US7087719B2 (en) 2002-11-19 2006-08-08 Gtc Biotherapeutics, Inc. Method for the crystallization of human serum albumin
US20040101939A1 (en) * 2002-11-22 2004-05-27 Santora Ling C. Method for reducing or preventing modification of a polypeptide in solution
BR0316643A (pt) 2002-11-27 2005-10-11 Gtc Biotherapeutics Inc Anticorpos modificados estavelmente produzidos no leite e método de produzir os mesmos
CN1735338A (zh) 2002-12-10 2006-02-15 Gtc生物治疗学公司 利用体细胞核转移胚胎作为细胞供体进行附加核转移的方法和系统
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
CA2516836A1 (en) 2003-02-24 2004-09-10 Gtc Biotherapeutics, Inc. Methods of tangential flow filtration and an apparatus therefore
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
CN1871252A (zh) 2003-09-05 2006-11-29 Gtc生物治疗学公司 在转基因哺乳动物奶中生产融合蛋白的方法
JP2007505604A (ja) 2003-09-15 2007-03-15 ジーティーシー バイオセラピューティクス， インコーポレイティド トランスジェニック動物の乳汁におけるドミナントネガティブ膜貫通型レセプターの発現
FR2861080B1 (fr) 2003-10-20 2006-02-17 Lab Francais Du Fractionnement Anticorps presentant un taux de fucose et de galactose optimise
ES2672640T3 (es) 2003-11-05 2018-06-15 Roche Glycart Ag Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
US20050169908A1 (en) 2004-01-23 2005-08-04 Kazunori Murakami Use of aerosolized antithrombin to treat acute lung injury
US20050186608A1 (en) 2004-02-19 2005-08-25 Olsen Byron V. Method for the production of transgenic proteins useful in the treatment of obesity and diabetes
US20050192226A1 (en) 2004-02-20 2005-09-01 Perenlei Enkhbaatar Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants
US20050197496A1 (en) 2004-03-04 2005-09-08 Gtc Biotherapeutics, Inc. Methods of protein fractionation using high performance tangential flow filtration
US7667089B2 (en) 2004-04-09 2010-02-23 National Chung Hsing University Transgenic mammal secreting B-domain deleted human FVII in its milk
US20060127950A1 (en) 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
US20060057638A1 (en) 2004-04-15 2006-03-16 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
US20050245444A1 (en) 2004-04-30 2005-11-03 Yann Echelard Method of using recombinant human antithrombin for neurocognitive disorders
WO2006014683A2 (en) 2004-07-21 2006-02-09 Glycofi, Inc. Immunoglobulins comprising predominantly a gal2glcnac2man3glcnac2 glycoform
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
US20060121004A1 (en) 2004-12-07 2006-06-08 Yann Echelard Methods of reducing the incidence of rejection in tissue transplantation through the use of recombinant human antithrombin
US20060123500A1 (en) 2004-12-07 2006-06-08 Gtc Biotherapeutics, Inc. Methods of prescreening cells for nuclear transfer procedures
US20060130159A1 (en) 2004-12-09 2006-06-15 Nick Masiello Method of purifying recombinant MSP 1-42 derived from Plasmodium falciparum
US20060168671A1 (en) 2005-01-21 2006-07-27 Gavin William G Injection of caprine sperm factor (cSF), phospholipase C zeta (PLCzeta) and adenophostin A as alternative methods of activation during nuclear transfer in the caprine species
US20080019905A9 (en) 2005-02-18 2008-01-24 Strome Scott E Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
WO2006088447A1 (en) 2005-02-15 2006-08-24 Gtc Biotherapeutics, Inc. An anti-cd137 antibody as an agent in the treatement of cancer and glycosylation variants thereof
US20060182744A1 (en) 2005-02-15 2006-08-17 Strome Scott E Anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof
EP1850872A4 (en) 2005-02-15 2008-10-15 Gtc Biotherapeutics Inc METHOD FOR USE OF ANTI-CD-137 ANTIBODY AS RADIOIMMUN THERAPY OR RADIO IMMUNE DETECTION MEANS
WO2006122787A1 (en) 2005-05-18 2006-11-23 Ablynx Nv Serum albumin binding proteins
US20060286548A1 (en) 2005-06-16 2006-12-21 Gregory Liposky Method of making recombinant human antibodies for use in biosensor technology
DK1896071T3 (en) * 2005-06-30 2015-05-26 Janssen Biotech Inc Methods and compositions with increased therapeutic activity
EP2468768A3 (en) * 2005-07-21 2012-10-31 Abbott Laboratories Multiple gene expression including sorf contructs and methods with polyproteins, pro-proteins, and proteolysis
WO2007014244A2 (en) 2005-07-25 2007-02-01 Gtc Biotherapeutics, Inc. Method of purifying recombinant human antithrombin to enhance the viral and prion safety profile
JP2009507482A (ja) 2005-09-09 2009-02-26 グライコフィ， インコーポレイテッド 主にｍａｎ７ｇｌｃｎａｃ２、ｍａｎ８ｇｌｃｎａｃ２グリコフォームを含むイムノグロブリン
ATE536373T1 (de) 2005-10-21 2011-12-15 Genzyme Corp Therapiemittel auf antikörperbasis mit erhöhter adcc-aktivität
KR20080068089A (ko) * 2005-10-21 2008-07-22 지티씨바이오쎄라퓨틱스,인크. 항체 의존성 세포 독성 활성이 증강된 항체, 그 생산 및사용 방법
UA99097C2 (ru) 2005-12-12 2012-07-25 Ф. Хоффманн-Ля Рош Аг Композиция, содержащая антитела к амилоиду бета 4, имеющие гликозилированный вариабельный участок
US7531632B2 (en) 2006-02-16 2009-05-12 Gtc Biotherapeutics, Inc. Clarification of transgenic milk using depth filtration
US8007790B2 (en) 2006-04-03 2011-08-30 Stowers Institute For Medical Research Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
CN101460522B (zh) 2006-04-11 2014-07-23 弗·哈夫曼-拉罗切有限公司 糖基化抗体
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
US8173860B2 (en) 2006-04-21 2012-05-08 Gtc Biotherapeutics, Inc. Non-human transgenic mammal expressing a human FcRn on its mammary gland cells and expressing a transgenic protein-human Fc-domain fusion
FR2901707B1 (fr) 2006-05-31 2017-09-29 Lab Francais Du Fractionnement Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis
CA2655246A1 (en) 2006-06-09 2007-12-21 University Of Maryland, Baltimore Glycosylation engineered antibody therapy
FR2904558B1 (fr) 2006-08-01 2008-10-17 Lab Francais Du Fractionnement "composition de facteur vii recombinant ou transgenique, presentant majoritairement des formes glycanniques biantennees, bisialylees et non fucosylees"
CN101588817B (zh) 2006-09-10 2013-06-12 葛莱高托普有限公司 骨髓白血病来源的细胞在抗体表达中的用途
SI2073842T1 (sl) * 2006-09-10 2015-05-29 Glycotope Gmbh Uporaba človeških celic izvirajočih iz mieloične levkemije za izražanje protiteles
WO2008063982A2 (en) 2006-11-13 2008-05-29 Procell Corp High mannose glycoprotein epitopes
CN101646775B (zh) * 2006-12-28 2016-08-24 森托科尔奥索生物科技公司 用于产生脱唾液酸化免疫球蛋白的方法和载体
WO2008101177A2 (en) 2007-02-16 2008-08-21 University Of Virginia Patent Foundation Ige antibodies to chimeric or humanized igg therapeutic monoclonal antibodies as a screening test for anaphylaxis
EP1985633A1 (en) 2007-04-26 2008-10-29 LFB Biotechnologies Kit of parts for the treatment of cancer or infectious diseases
CN105131127B (zh) 2007-05-30 2018-09-07 浦项工科大学校产学协力团 免疫球蛋白融合蛋白
MX2009013421A (es) 2007-06-13 2010-03-22 Sterrenbeld Biotechnologie North America Inc Mamiferos transgenicos que producen proteinas exogenas en su leche.
EP2725035A1 (en) * 2007-10-02 2014-04-30 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
EP2225276B1 (en) * 2007-12-31 2014-04-23 Bayer Intellectual Property GmbH Antibodies to tnf alpha
WO2009088998A2 (en) 2008-01-07 2009-07-16 Synageva Biopharma Corp. Glycosylation in avians
WO2009134389A2 (en) 2008-05-01 2009-11-05 Gtc Biotherapeutics, Inc. An anti-cd137 antibody as an agent in the treatment of inflammatory conditions
WO2010036443A1 (en) 2008-09-26 2010-04-01 Eureka Therapeutics, Inc. Cell lines and proteins with variant glycosylation pattern
US20100178292A1 (en) 2009-01-12 2010-07-15 The Board Of Trustees Of The Leland Stanford Junior University Cryptic glycan markers and applications thereof
US20110082083A1 (en) 2009-04-10 2011-04-07 Gtc Biotherapeutics, Inc. Formulations of liquid stable antithrombin
KR20140014405A (ko) 2009-05-28 2014-02-06 글락소 그룹 리미티드 안구 질병을 치료하거나 예방하는데 사용되는 ｔｎｆ-알파 길항제 및 ｖｅｇｆ 길항제의 조합물
KR20140093603A (ko) 2010-12-30 2014-07-28 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 병원체 불활성화제로서의 글리콜
JPWO2012105699A1 (ja) * 2011-02-03 2014-07-03 株式会社イーベック 補体依存性生物活性の高い抗体の産生法
KR20140054026A (ko) 2011-07-07 2014-05-08 알에보 바이올로직스, 인코포레이티드 단백질을 안정화시키는 제제
WO2013021279A2 (en) 2011-08-10 2013-02-14 Lfb Biotechnologies Highly galactosylated antibodies
KR101454316B1 (ko) 2011-08-17 2014-10-27 한화케미칼 주식회사 활성형 ＴＮＦＲ-Ｆｃ 융합 단백질을 제조하는 방법
US20130302274A1 (en) 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
BR112014014751A8 (pt) 2011-12-19 2017-07-04 Lfb Usa Inc composição compreendendo alfa-1-antitripsina, células epiteliais de glândula mamária, mamífero não humano transgênico, e, método para reduzir a atividade de elastase no pulmão
TW201400499A (zh) 2012-03-12 2014-01-01 Revo Biolog Inc 抗凝血酶用於治療妊娠毒血症之用途
WO2013188870A2 (en) 2012-06-15 2013-12-19 Beth Israel Deaconess Medical Center, Inc. IgA CD4i ANTIBODIES AND METHODS OF TREATMENT USING SAME
TW201425332A (zh) 2012-08-03 2014-07-01 Revo Biolog Inc 抗凝血酶用於體外膜氧合之用途
WO2014040024A1 (en) 2012-09-10 2014-03-13 Revo Biologics, Inc. The use of antibodies in treating hiv infection and suppressing hiv transmission
TW201444871A (zh) 2013-02-13 2014-12-01 Lab Francais Du Fractionnement 具有修飾的糖化作用之西妥昔單抗及其用途
EP3594231A1 (en) 2013-02-13 2020-01-15 Laboratoire Français du Fractionnement et des Biotechnologies Highly galactosylated anti-tnf-alpha antibodies and uses thereof
EP2956485A2 (en) 2013-02-13 2015-12-23 Laboratoire Français du Fractionnement et des Biotechnologies Highly galactosylated anti-her2 antibodies and uses thereof
US10034921B2 (en) 2013-02-13 2018-07-31 Laboratoire Français Du Fractionnement Et Des Biotechnologies Proteins with modified glycosylation and methods of production thereof
FR3005576B1 (fr) 2013-05-15 2015-06-19 Lab Francais Du Fractionnement Procede d'inactivation d'une proteine prion
MX384222B (es) 2013-07-05 2025-03-14 Lab Francais Du Fractionnement Matriz de cromatografia de afinidad.
FR3015484A1 (fr) 2013-12-20 2015-06-26 Lab Francais Du Fractionnement Proteines recombinantes possedant une activite de facteur h
CN105828603A (zh) 2013-12-24 2016-08-03 Lfb美国股份有限公司 肝素的转基因生产
AU2015270152A1 (en) 2014-06-02 2016-12-08 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Production of Fc fragments
FR3022462B1 (fr) 2014-06-18 2018-04-27 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Composition orale d'anticorps anti-tnfalpha
US20160158676A1 (en) 2014-12-01 2016-06-09 Laboratoire Français Du Fractionnement Et Des Biotechnologies Method and apparatus for manipulating components of a filtration system

Also Published As

Publication number Publication date
CA2900909A1 (en) 2014-08-21
EP3594230A1 (en) 2020-01-15
US10174110B2 (en) 2019-01-08
MX2015010427A (es) 2016-03-17
ES2755181T3 (es) 2020-04-21
TW201506041A (zh) 2015-02-16
BR112015019341A2 (pt) 2017-08-22
US20190309058A1 (en) 2019-10-10
EP3594231A1 (en) 2020-01-15
WO2014125374A2 (en) 2014-08-21
AU2014217561B2 (en) 2018-11-15
KR20160002713A (ko) 2016-01-08
US20150368334A1 (en) 2015-12-24
EP2956480A2 (en) 2015-12-23
CN105308068A (zh) 2016-02-03
AU2014217561A1 (en) 2015-08-27
US20190309057A1 (en) 2019-10-10
AR094780A1 (es) 2015-08-26
JP2016508515A (ja) 2016-03-22
EP2956480B1 (en) 2019-09-04
JP2020073550A (ja) 2020-05-14
WO2014125374A3 (en) 2014-12-31

Similar Documents

Publication Publication Date Title
IL261743B (en) and their uses 33–il antibodies against
IL240443A0 (en) Antibodies against tnf-a with a high level of galactosylation and their uses
IL261547B (en) Antibodies against pesidine and their uses
IL245040A0 (en) Antibodies against pdgfr-beta and their uses
IL243974A0 (en) Antibodies against -prlr and uses
ZA201508896B (en) Anti-c10orf54 antibodies and uses thereof
EP2953970A4 (en) TRANSTYRETIN ANTIBODIES AND USES THEREOF
IL246287A0 (en) Fabs antibodies one by one and their uses
SG11201509618QA (en) Anti-b7-h5 antibodies and their uses
IL243822B (en) Anti-activin a antibodies and their uses
IL240438A0 (en) New antibody conjugates and their uses
SG11201509116VA (en) Anti-tweakr antibodies and uses thereof
IL240440A0 (en) Antibodies against her2 with a high level of galactosylation and their uses
SG11201602760YA (en) Monoclonal olfml-3 antibodies and uses thereof
EP3066122A4 (en) Pre-haptoglobin-2 monoclonal antibodies and uses thereof
ZA201603596B (en) Fabs-in-tandem immunoglobulin and uses thereof
AU2013901830A0 (en) Antibodies and uses thereof